Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Endometrial Cancer-Pipeline Review, H1 2015

Endometrial Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Endometrial Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Endometrial Cancer-Pipeline Review, H1 2015', provides an overview of the Endometrial Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Endometrial Cancer Overview 8

Therapeutics Development 9

Pipeline Products for Endometrial Cancer-Overview 9

Pipeline Products for Endometrial Cancer-Comparative Analysis 10

Endometrial Cancer-Therapeutics under Development by Companies 11

Endometrial Cancer-Therapeutics under Investigation by Universities/Institutes 15

Endometrial Cancer-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Endometrial Cancer-Products under Development by Companies 19

Endometrial Cancer-Products under Investigation by Universities/Institutes 22

Endometrial Cancer-Companies Involved in Therapeutics Development 23

Acceleron Pharma, Inc. 23

Aeterna Zentaris Inc. 24

Ariad Pharmaceuticals, Inc. 25

Arno Therapeutics, Inc. 26

ArQule, Inc. 27

AstraZeneca Plc 28

AVEO Pharmaceuticals, Inc. 29

BioMarin Pharmaceutical Inc. 30

Boehringer Ingelheim GmbH 31

Critical Outcome Technologies Inc. 32

Daiichi Sankyo Company, Limited 33

Eisai Co., Ltd. 34

Esperance Pharmaceuticals, Inc. 35

Exelixis, Inc. 36

Farmsintez 37

Galena Biopharma, Inc. 38

Genentech, Inc. 39

Genmab A/S 40

GlaxoSmithKline Plc 41

Gradalis Inc. 42

ImmunoGen, Inc. 43

Incyte Corporation 44

Karyopharm Therapeutics, Inc. 45

Merck & Co., Inc. 46

Merck KGaA 47

Millennium Pharmaceuticals, Inc. 48

Novartis AG 49

OncoHoldings, Inc. 50

Oncothyreon Inc. 51

Otsuka Holdings Co., Ltd. 52

Pharma Mar, S.A. 53

Puma Biotechnology, Inc. 54

Sanofi 55

Scancell Holdings Plc 56

Shenogen Pharma Group Ltd. 57

Endometrial Cancer-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Combination Products 59

Assessment by Target 60

Assessment by Mechanism of Action 64

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

(ponatinib hydrochloride + ridaforolimus)-Drug Profile 71

Pb-TCMC-Trastuzumab-Drug Profile 72

AEZS-125-Drug Profile 74

afuresertib hydrochloride + trametinib dimethyl sulfoxide-Drug Profile 75

ARQ-092-Drug Profile 76

AV-203-Drug Profile 77

AZD-2014-Drug Profile 78

AZD-5363-Drug Profile 80

buparlisib hydrochloride-Drug Profile 82

cabozantinib s-malate-Drug Profile 86

cancer vaccine-Drug Profile 89

Cell Therapy for Oncology-Drug Profile 91

CLR-457-Drug Profile 92

COTI-2-Drug Profile 93

cridanimod-Drug Profile 96

dalantercept-Drug Profile 97

EP-200-Drug Profile 99

epacadostat-Drug Profile 100

everolimus-Drug Profile 102

FROST-450-Drug Profile 107

GALE-301-Drug Profile 108

GDC-0927-Drug Profile 110

GSK-2636771-Drug Profile 111

HO-3867-Drug Profile 112

HuMax-TF-ADC-Drug Profile 113

INCB-54828-Drug Profile 114

lenvatinib-Drug Profile 115

lurbinectedin-Drug Profile 119

mirvetuximab soravtansine-Drug Profile 122

MK-2206-Drug Profile 124

Modi-1-Drug Profile 127

Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer-Drug Profile 128

neratinib-Drug Profile 129

nintedanib-Drug Profile 133

onapristone ER-Drug Profile 138

ONCO-101-Drug Profile 140

ONT-10-Drug Profile 141

OPB-111001-Drug Profile 143

patritumab-Drug Profile 144

Peptides to Inhibit GnRH II Receptor for Oncology-Drug Profile 146

pimasertib hydrochloride + voxtalisib-Drug Profile 147

sapanisertib-Drug Profile 149

SAR-408701-Drug Profile 151

selinexor-Drug Profile 152

SERD-2-Drug Profile 157

SNG-1153-Drug Profile 158

talazoparib-Drug Profile 159

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 162

zoptarelin doxorubicin-Drug Profile 164

Endometrial Cancer-Recent Pipeline Updates 166

Endometrial Cancer-Dormant Projects 247

Endometrial Cancer-Discontinued Products 250

Endometrial Cancer-Product Development Milestones 251

Featured News & Press Releases 251

Appendix 260

Methodology 260

Coverage 260

Secondary Research 260

Primary Research 260

Expert Panel Validation 260

Contact Us 260

Disclaimer 261

List of Tables

Number of Products under Development for Endometrial Cancer, H1 2015 13

Number of Products under Development for Endometrial Cancer-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Endometrial Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 27

Endometrial Cancer-Pipeline by Aeterna Zentaris Inc., H1 2015 28

Endometrial Cancer-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 29

Endometrial Cancer-Pipeline by Arno Therapeutics, Inc., H1 2015 30

Endometrial Cancer-Pipeline by ArQule, Inc., H1 2015 31

Endometrial Cancer-Pipeline by AstraZeneca Plc, H1 2015 32

Endometrial Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 33

Endometrial Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 34

Endometrial Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 35

Endometrial Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 36

Endometrial Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 37

Endometrial Cancer-Pipeline by Eisai Co., Ltd., H1 2015 38

Endometrial Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 39

Endometrial Cancer-Pipeline by Exelixis, Inc., H1 2015 40

Endometrial Cancer-Pipeline by Farmsintez, H1 2015 41

Endometrial Cancer-Pipeline by Galena Biopharma, Inc., H1 2015 42

Endometrial Cancer-Pipeline by Genentech, Inc., H1 2015 43

Endometrial Cancer-Pipeline by Genmab A/S, H1 2015 44

Endometrial Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 45

Endometrial Cancer-Pipeline by Gradalis Inc., H1 2015 46

Endometrial Cancer-Pipeline by ImmunoGen, Inc., H1 2015 47

Endometrial Cancer-Pipeline by Incyte Corporation, H1 2015 48

Endometrial Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 49

Endometrial Cancer-Pipeline by Merck & Co., Inc., H1 2015 50

Endometrial Cancer-Pipeline by Merck KGaA, H1 2015 51

Endometrial Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 52

Endometrial Cancer-Pipeline by Novartis AG, H1 2015 53

Endometrial Cancer-Pipeline by OncoHoldings, Inc., H1 2015 54

Endometrial Cancer-Pipeline by Oncothyreon Inc., H1 2015 55

Endometrial Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 56

Endometrial Cancer-Pipeline by Pharma Mar, S.A., H1 2015 57

Endometrial Cancer-Pipeline by Puma Biotechnology, Inc., H1 2015 58

Endometrial Cancer-Pipeline by Sanofi, H1 2015 59

Endometrial Cancer-Pipeline by Scancell Holdings Plc, H1 2015 60

Endometrial Cancer-Pipeline by Shenogen Pharma Group Ltd., H1 2015 61

Assessment by Monotherapy Products, H1 2015 62

Assessment by Combination Products, H1 2015 63

Number of Products by Stage and Target, H1 2015 65

Number of Products by Stage and Mechanism of Action, H1 2015 69

Number of Products by Stage and Route of Administration, H1 2015 72

Number of Products by Stage and Molecule Type, H1 2015 74

Endometrial Cancer Therapeutics-Recent Pipeline Updates, H1 2015 170

Endometrial Cancer-Dormant Projects, H1 2015 251

Endometrial Cancer-Dormant Projects (Contd..1), H1 2015 252

Endometrial Cancer-Dormant Projects (Contd..2), H1 2015 253

Endometrial Cancer-Discontinued Products, H1 2015 254

List of Figures

Number of Products under Development for Endometrial Cancer, H1 2015 13

Number of Products under Development for Endometrial Cancer-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 62

Assessment by Combination Products, H1 2015 63

Number of Products by Top 10 Targets, H1 2015 64

Number of Products by Stage and Top 10 Targets, H1 2015 64

Number of Products by Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Top 10 Routes of Administration, H1 2015 71

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 72

Number of Products by Top 10 Molecule Types, H1 2015 73

Number of Products by Stage and Top 10 Molecule Types, H1 2015 74

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Aeterna Zentaris Inc.

Ariad Pharmaceuticals, Inc.

Arno Therapeutics, Inc.

ArQule, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc.

Boehringer Ingelheim GmbH

Critical Outcome Technologies Inc.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

Farmsintez

Galena Biopharma, Inc.

Genentech, Inc.

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc.

ImmunoGen, Inc.

Incyte Corporation

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Novartis AG

OncoHoldings, Inc.

Oncothyreon Inc.

Otsuka Holdings Co., Ltd.

Pharma Mar, S.A.

Puma Biotechnology, Inc.

Sanofi

Scancell Holdings Plc

Shenogen Pharma Group Ltd.

Endometrial Cancer Therapeutic Products under Development, Key Players in Endometrial Cancer Therapeutics, Endometrial Cancer Pipeline Overview, Endometrial Cancer Pipeline, Endometrial Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com